Literature DB >> 28466424

Naldemedine: First Global Approval.

Anthony Markham1.   

Abstract

Naldemedine (Symproic®) is an orally active µ-opioid receptor antagonist being developed by Shionogi & Co., Ltd. that has been approved in the USA and Japan for the treatment of opioid-induced constipation. The drug inhibits peripheral µ-opioid receptors such as those present in the gastrointestinal tract and has minimal or no effect on central opioid activity. This article summarizes the milestones in the development of naldemedine leading to its first global approval in the USA for the treatment of opioid-induced constipation in patients with chronic non-cancer pain.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28466424     DOI： 10.1007/s40265-017-0750-0

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   11.431


  2 in total

Review 1.  Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation.

Authors:  M Camilleri; D A Drossman; G Becker; L R Webster; A N Davies; G M Mawe
Journal:  Neurogastroenterol Motil       Date:  2014-08-28       Impact factor: 3.598

2.  A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.

Authors:  Lynn R Webster; Tadaaki Yamada; Juan Camilo Arjona Ferreira
Journal:  Pain Med       Date:  2017-12-01       Impact factor: 3.637
  2 in total
  10 in total

1.  Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor Antagonist.

Authors:  Daniel D Long; Scott R Armstrong; David T Beattie; Christina B Campbell; Timothy J Church; Pierre-Jean Colson; Sean M Dalziel; John R Jacobsen; Lan Jiang; Glenmar P Obedencio; Miroslav Rapta; Daisuke Saito; Ioanna Stergiades; Pamela R Tsuruda; Priscilla M Van Dyke; Ross G Vickery
Journal:  ACS Med Chem Lett       Date:  2019-11-26       Impact factor: 4.345

2.  Naldemedine (Symproic) for the Treatment Of Opioid-Induced Constipation.

Authors:  Kenneth Hu; Mary Barna Bridgeman
Journal:  P T       Date:  2018-10

3.  Synthesis of Benzannulated Medium-ring Lactams via a Tandem Oxidative Dearomatization-Ring Expansion Reaction.

Authors:  Tezcan Guney; Todd A Wenderski; Matthew W Boudreau; Derek S Tan
Journal:  Chemistry       Date:  2018-08-02       Impact factor: 5.236

Review 4.  Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice.

Authors:  Ana Fernández-Montes; Guillermo de Velasco; Santiago Aguín; Cristina Farriols; María Guirado-Risueño; Vanessa G Jerviz-Guía; María Victoria Baeza-Nadal; Rodolfo Chicas-Sett; José Luis Fírvida; Francisco García-Navalón; Patricia Martín; Carmen Perezagua-Marín; Dulce Rodríguez; Joan Santamaría; Tamara Saurí; Manuel Cobo
Journal:  Curr Treat Options Oncol       Date:  2021-02-26

5.  The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine.

Authors:  Kazuya Fukumura; Tadaaki Yamada; Takaaki Yokota; Akira Kawasaki
Journal:  Clin Pharmacol Drug Dev       Date:  2019-04-12

Review 6.  Opioid-Induced Constipation in Oncological Patients: New Strategies of Management.

Authors:  Ricard Mesía; Juan Antonio Virizuela Echaburu; Jose Gómez; Tamara Sauri; Gloria Serrano; Eduardo Pujol
Journal:  Curr Treat Options Oncol       Date:  2019-12-19

Review 7.  Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain.

Authors:  Joelle BouSaba; Wassel Sannaa; Michael Camilleri
Journal:  Therap Adv Gastroenterol       Date:  2022-04-28       Impact factor: 4.409

Review 8.  Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy.

Authors:  Emily K Stern; Darren M Brenner
Journal:  J Pain Res       Date:  2018-01-15       Impact factor: 3.133

9.  Population Pharmacokinetics and Exposure-Response Relationships of Naldemedine.

Authors:  Ryuji Kubota; Kazuya Fukumura; Toshihiro Wajima
Journal:  Pharm Res       Date:  2018-10-02       Impact factor: 4.580

Review 10.  Naldemedine for the Use of Management of Opioid Induced Constipation.

Authors:  Ivan Urits; Anjana Patel; Hayley Cornwall Kiernan; Conner Joseph Clay; Nikolas Monteferrante; Jai Won Jung; Amnon A Berger; Hisham Kassem; Jamal Hasoon; Alan D Kaye; Adam M Kaye; Omar Viswanath
Journal:  Psychopharmacol Bull       Date:  2020-07-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.